<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00951288</url>
  </required_header>
  <id_info>
    <org_study_id>SafAMD</org_study_id>
    <nct_id>NCT00951288</nct_id>
  </id_info>
  <brief_title>Effect of Saffron Supplementation on Macular Cone-mediated Function in Age-related Macular Degeneration</brief_title>
  <acronym>safAMD</acronym>
  <official_title>Effect of Saffron Supplementation on Macular Cone-mediated Function in Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot interventional study whose aim is to determine the effect of a dietary&#xD;
      supplementation with a Crocus Sativus extract, Saffron, on macular cone-mediated function in&#xD;
      patients with early age-related macular degeneration (AMD). Pre-clinical evidence ( Maccarone&#xD;
      R, Di Marco S, Bisti S. Saffron supplement maintains morphology and function after exposure&#xD;
      to damaging light in mammalian retina. Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1254-61.)&#xD;
      indicates the potential effectiveness of Saffron as a retinal neuroprotectant in animal&#xD;
      models of retinal degenerative disorders.The macular function will be tested by visual acuity&#xD;
      and macular cone-mediated electroretinogram (focal electroretinogram, FERG) according to a&#xD;
      standardized technique (see citations).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A group of 30 AMD patients with typical lesions (drusen and/or retinal pigment epithelial&#xD;
      defects) and relatively preserved central retinal function and visual acuity will be&#xD;
      enrolled. AMD patients will be randomly divided into two groups: 1. placebo group [n = 15),&#xD;
      taking for three months an oral placebo; 2. Saffron group (n = 15), taking Saffron oral&#xD;
      treatment (20 mg/day) for three months. After three months of placebo or Saffron&#xD;
      supplementation, patients will be tested with standard ophthalmic examination and FERGs.&#xD;
      Then, placebo with Saffron and vice-versa will be changed to the same patients in a&#xD;
      cross-over design. After a further three month period of placebo or study drug&#xD;
      supplementation, patients will undergo again a standard ophthalmic examination, and FERG.&#xD;
      Throughout the study, both patients and experimenters will be masked as to the identity of&#xD;
      pills (i.e. whether placebo or study drug), whose identification key number will be kept in a&#xD;
      sealed envelope that will be opened only at the completion of the study. Therapeutic&#xD;
      compliance will be tested by careful questioning, either at two weeks of treatment (by&#xD;
      telephone interview) or at the end of the treatment period, as well as by pill count. Main&#xD;
      outcome measures of the study will be FERG amplitude and phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Focal Electroretinogram Amplitude and Phase</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Saffron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Crocus Sativus extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saffron</intervention_name>
    <description>Saffron 20 mg/day supplementation</description>
    <arm_group_label>Saffron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 55 yrs&#xD;
&#xD;
          -  Diagnosis of Early, non exudative AMD&#xD;
&#xD;
          -  Visual acuity of 20/40 or better&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant ocular or systemic disorders which may affect macular function&#xD;
&#xD;
          -  Drugs that may affect macular function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedetto Falsini, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinico A. Gemelli, Institute of Ophthalmology</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Maccarone R, Di Marco S, Bisti S. Saffron supplement maintains morphology and function after exposure to damaging light in mammalian retina. Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1254-61. doi: 10.1167/iovs.07-0438.</citation>
    <PMID>18326756</PMID>
  </reference>
  <reference>
    <citation>Falsini B, Piccardi M, Iarossi G, Fadda A, Merendino E, Valentini P. Influence of short-term antioxidant supplementation on macular function in age-related maculopathy: a pilot study including electrophysiologic assessment. Ophthalmology. 2003 Jan;110(1):51-60; discussion 61.</citation>
    <PMID>12511345</PMID>
  </reference>
  <reference>
    <citation>Falsini B, Fadda A, Iarossi G, Piccardi M, Canu D, Minnella A, Serrao S, Scullica L. Retinal sensitivity to flicker modulation: reduced by early age-related maculopathy. Invest Ophthalmol Vis Sci. 2000 May;41(6):1498-506.</citation>
    <PMID>10798669</PMID>
  </reference>
  <results_reference>
    <citation>Falsini B, Piccardi M, Minnella A, Savastano C, Capoluongo E, Fadda A, Balestrazzi E, Maccarone R, Bisti S. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6118-24. doi: 10.1167/iovs.09-4995. Epub 2010 Aug 4.</citation>
    <PMID>20688744</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>August 3, 2009</study_first_submitted>
  <study_first_submitted_qc>August 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2009</study_first_posted>
  <last_update_submitted>July 31, 2015</last_update_submitted>
  <last_update_submitted_qc>July 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Benedetto Falsini</investigator_full_name>
    <investigator_title>Associate Professor, Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>Retinal Function</keyword>
  <keyword>Neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

